Literature DB >> 29530851

Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam.

Melissa D Barnes1,2, Christopher R Bethel1, Jim Alsop3, Scott A Becka1, Joseph D Rutter1, Krisztina M Papp-Wallace4,2,5,6, Robert A Bonomo4,2,7,8,5,6,9,10.   

Abstract

Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen. Pseudomonas-derived cephlosporinase (PDC) is the major inducible cephalosporinase in P. aeruginosa In this investigation, we show that relebactam, a diazabicyclooctane β-lactamase inhibitor, potently inactivates PDC-3, with a k2/K of 41,400 M-1 s-1 and a koff of 0.00095 s-1 Relebactam restored susceptibility to imipenem in 62% of multidrug-resistant P. aeruginosa clinical isolates, while only 21% of isolates were susceptible to imipenem-cilastatin alone. Relebactam promises to increase the efficacy of imipenem-cilastatin against P. aeruginosa.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  AmpC; PDC-3; Pseudomonas aeruginosa; diazabicyclooctane inhibitor; imipenem; relebactam; β-lactam; β-lactamase

Mesh：

Substances：

Year:  2018        PMID： 29530851      PMCID： PMC5923161          DOI： 10.1128/AAC.02406-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  Variants of β-lactamase KPC-2 that are resistant to inhibition by avibactam.

Authors:  Krisztina M Papp-Wallace; Marisa L Winkler; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

2.  Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013.

Authors:  Helio S Sader; Mariana Castanheira; Rodrigo E Mendes; Robert K Flamm; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2015-04-06       Impact factor: 5.191

3.  Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin®.

Authors:  Timothy A Blizzard; Helen Chen; Seongkon Kim; Jane Wu; Rena Bodner; Candido Gude; Jason Imbriglio; Katherine Young; Young-Whan Park; Aimie Ogawa; Susan Raghoobar; Nichelle Hairston; Ronald E Painter; Doug Wisniewski; Giovanna Scapin; Paula Fitzgerald; Nandini Sharma; Jun Lu; Sookhee Ha; Jeff Hermes; Milton L Hammond
Journal:  Bioorg Med Chem Lett       Date:  2014-01-03       Impact factor: 2.823

4.  Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase.

Authors:  Sarah M Drawz; Magdalena Taracila; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Protein Sci       Date:  2011-05-03       Impact factor: 6.725

5.  In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.

Authors:  Elizabeth B Hirsch; Kimberly R Ledesma; Kai-Tai Chang; Michael S Schwartz; Mary R Motyl; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

6.  Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2015-05-08       Impact factor: 5.790

7.  Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor.

Authors:  David E Ehmann; Haris Jahić; Philip L Ross; Rong-Fang Gu; Jun Hu; Gunther Kern; Grant K Walkup; Stewart L Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

8.  Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

Authors:  Matthew Sims; Valeri Mariyanovski; Patrick McLeroth; Wayne Akers; Yu-Chieh Lee; Michelle L Brown; Jiejun Du; Alison Pedley; Nicholas A Kartsonis; Amanda Paschke
Journal:  J Antimicrob Chemother       Date:  2017-09-01       Impact factor: 5.790

9.  Extended-spectrum cephalosporinases in Pseudomonas aeruginosa.

Authors:  José-Manuel Rodríguez-Martínez; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

10.  Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Authors:  Melissa D Barnes; Marisa L Winkler; Magdalena A Taracila; Malcolm G Page; Eric Desarbre; Barry N Kreiswirth; Ryan K Shields; Minh-Hong Nguyen; Cornelius Clancy; Brad Spellberg; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867
View more
  12 in total

Review 1.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

Review 2.  The Taxonomy of Covalent Inhibitors.

Authors:  Alfred Tuley; Walter Fast
Journal:  Biochemistry       Date:  2018-04-30       Impact factor: 3.162

Review 3.  The latest advances in β-lactam/β-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections.

Authors:  Krisztina M Papp-Wallace
Journal:  Expert Opin Pharmacother       Date:  2019-09-09       Impact factor: 3.889

Review 4.  Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections.

Authors:  Young-A Heo
Journal:  Drugs       Date:  2021-02-25       Impact factor: 9.546

Review 5.  New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.

Authors:  Juan C Vázquez-Ucha; Jorge Arca-Suárez; Germán Bou; Alejandro Beceiro
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

Review 6.  A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Authors:  Toni A Campanella; Jason C Gallagher
Journal:  Infect Drug Resist       Date:  2020-11-25       Impact factor: 4.003

7.  Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli.

Authors:  Scott A Becka; Elise T Zeiser; John J LiPuma; Krisztina M Papp-Wallace
Journal:  Antimicrob Agents Chemother       Date:  2021-08-09       Impact factor: 5.191

8.  Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.

Authors:  Catherine L Tooke; Philip Hinchliffe; Pauline A Lang; Adrian J Mulholland; Jürgen Brem; Christopher J Schofield; James Spencer
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.938

Review 9.  The Building Blocks of Antimicrobial Resistance in Pseudomonas aeruginosa: Implications for Current Resistance-Breaking Therapies.

Authors:  R Frèdi Langendonk; Daniel R Neill; Joanne L Fothergill
Journal:  Front Cell Infect Microbiol       Date:  2021-04-16       Impact factor: 5.293

10.  Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance.

Authors:  Patricia J Simner; Stephan Beisken; Yehudit Bergman; Andreas E Posch; Sara E Cosgrove; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2021-06-12       Impact factor: 3.835
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.